| Eligibility |
Inclusion Criteria:
1. Age: = 10 years old and = 75 years old, male or female;
2. Meet the diagnostic criteria for recurrent AML: detection of leukemia cells after
complete remission (CR) or >0.1% of leukemia cells in bone marrow, including
recurrence after allogeneic hematopoietic stem cell transplantation, or extramedullary
infiltration of leukemia cells;
3. Initial cases with failure of 2 lines of standard treatment; patients who relapsed
within 12 months after consolidation intensification after CR; recurrence in 12 months
and no respond to conventional chemotherapy; 2 or more recurrences; persistent
extramedullarial leukemia;
4. Patients currently have no effective treatment options, such as chemotherapy or
allogeneic hematopoietic stem cell transplantation, or patients voluntarily choose to
infuse NKG2D CAR-NK cells as the first treatment option;
5. Physical status assessment (ECOG-PS) of the Eastern Oncology Collaborative Group is
0-2 points;
6. Estimated survival > 3 months
7. Flow cytometry check for NKG2D ligand expression on the surface of cancer cells for a
reference of selecting patients
8. The main organs of the patient are well functioned: (1) cardiac function: no heart
disease or coronary heart disease, the patient's cardiac function grade 1-2; (2) liver
function: TBIL?3ULN, AST?2.5ULN, ALT?2.5ULN; (3) Renal function: Cr?1.25ULN;
9. The patient's peripheral superficial vein can meet the needs of intravenous injection;
10. No other serious diseases that conflict with this protocol (e.g., autoimmune diseases,
immunodeficiency, organ transplantation);
11. No history of other malignant tumors;
12. Women of childbearing age must be tested negative for pregnancy within 7 days, and
subjects of childbearing age must use appropriate contraception during both the trial
and for 3 months after the test;
13. Subjects have negative HIV, HBV, HCV, syphilis serology test results
14. Written informed consent form must be signed before enrollment.
Exclusion Criteria:
1. Acute promyelocytic leukemia (type M3);
2. Patients with cardiac insufficiency, patients with hepatic and renal insufficiency;
3. Those who need treatment with other malignant tumors;
4. Poorly controlled hypertension (systolic blood pressure >160 mmHg and/or diastolic
blood pressure >90 mmHg) or clinically significant cardiovascular and cerebrovascular
diseases such as cerebrovascular accident (within 6 months before signing the informed
consent form), myocardial infarction (within 6 months before signing the informed
consent), unstable angina, congestive heart failure, or severe arrhythmias that cannot
be controlled with drugs or have a potential impact on research treatment;
5. Also suffering from other hematologic diseases (such as hemophilia, myelofibrosis,
etc., which researchers consider unsuitable for inductees);
6. Diffuse vascular internal coagulation;
7. Concomitant serious infection or other serious underlying medical condition;
8. Have immunodeficiency and autoimmune diseases;
9. Have severe allergic diseases;
10. Clinical symptoms of brain dysfunction or severe mental illness that can not
understand or follow the research protocol;
11. Have participated in clinical trials of other drugs within 4 weeks or within 21 days
of surgery;
12. Have received cell therapy in the previous 1 month;
13. Have received hormonal drug therapy in the previous 14 days;
14. Known HIV-positive patients or hepatitis B and C patients and syphilis patients;
15. Have received organ transplants (excluding stem cell transplant patients);
16. Drug abuse, medical, psychological or social conditions that may interfere with a
subject's participation in the study or evaluation of the results of the study;
17. Pregnant or lactating women;
18. Those who cannot be followed up as scheduled;
19. Investigator considers that the subject has any clinical or laboratory abnormalities
or compliance problems and is not suitable to participate in this clinical study.
|
